Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 101–200 of 1,001
Do Interactions Between Gut Ecology and Environmental Chemicals Contribute to Obesity and Diabetes?
Snedeker, S. M., & Hay, A. G. (2012) · Environmental Health Perspectives · doi:10.1289/ehp.1104204 · Cited by 184
The Microbiome and Genitourinary Cancer: A Collaborative Review
Markowski, M. C., Boorjian, S. A., Burton, J. P., Hahn, N. M., Ingersoll, M. A., Maleki Vareki, S., Pal, S. K., & Sfanos, K. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.043 · Cited by 182
Microbial Contribution to the Human Metabolome: Implications for Health and Disease
Van Treuren, W., & Dodd, D. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043559 · Cited by 181
Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
Swanson, H. I. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065714 · Cited by 178
Human microbiome signatures of differential colorectal cancer drug metabolism
Guthrie, L., Gupta, S., Daily, J., & Kelly, L. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0034-1 · Cited by 156
Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites
Guo, Y., Crnkovic, C. M., Won, K., Yang, X., Lee, J. R., Orjala, J., Lee, H., & Jeong, H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084772 · Cited by 177
Long, Y., Wu, M., Kwoh, C. K., Luo, J., & Li, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa598 · Cited by 174
Meta'omic Analytic Techniques for Studying the Intestinal Microbiome
Morgan, X. C., & Huttenhower, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.049 · Cited by 173
Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Shanahan, F., & Quigley, E. M. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.050 · Cited by 172
Xue, M., Ji, X., Liang, H., Liu, Y., Wang, B., Sun, L., & Li, W. (2018) · Food & Function · doi:10.1039/c7fo01677h · Cited by 172
Lam, K. N., Spanogiannopoulos, P., Soto-Perez, P., Alexander, M., Nalley, M. J., Bisanz, J. E., Nayak, R. R., Weakley, A. M., Yu, F. B., & Turnbaugh, P. J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109930 · Cited by 172
Utilization of the microbiome in personalized medicine
Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00998-9 · Cited by 170
Therapeutic significance of β-glucuronidase activity and its inhibitors: A review
Awolade, P., Cele, N., Kerru, N., Gummidi, L., Oluwakemi, E., & Singh, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111921 · Cited by 179
The Gut Microbiome and Sex Hormone-Related Diseases
He, S., Li, H., Yu, Z., Zhang, F., Liang, S., Liu, H., Chen, H., & Lü, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.711137 · Cited by 169
Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease
Mehta, R. S., Mayers, J. R., Zhang, Y., Bhosle, A., Glasser, N. R., Nguyen, L. H., Ma, W., Bae, S., Branck, T., Song, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02217-7 · Cited by 168
Saitta, K. S., Zhang, C., Lee, K. K., Fujimoto, K., Redinbo, M. R., & Boelsterli, U. A. (2014) · Xenobiotica · doi:10.3109/00498254.2013.811314 · Cited by 165
“for Inh-1 was adopted from a previously published study (Wallace et al., 2010).”
BackgroundMethodSelf-citationGori, S., Inno, A., Belluomini, L., Bocus, P., Bisoffi, Z., Russo, A., & Arcaro, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.003 · Cited by 165
Psychotropics and the Microbiome: a Chamber of Secrets…
Cussotto, S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5185-8 · Cited by 163
The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer
Sui, Y., Wu, J., & Chen, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631552 · Cited by 162
NSAID–Gut Microbiota Interactions
Maseda, D., & Ricciotti, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01153 · Cited by 159
Sfanos, K. S., Markowski, M. C., Peiffer, L. B., Ernst, S. E., White, J. R., Pienta, K. J., Antonarakis, E. S., & Ross, A. E. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0061-x · Cited by 147
Gut microbiota modulates drug pharmacokinetics
Zhang, J., Zhang, J., & Wang, R. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1497647 · Cited by 150
Toward Understanding Microbiome-Neuronal Signaling
Jameson, K. G., Olson, C. A., Kazmi, S. A., & Hsiao, E. Y. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.03.006 · Cited by 149
Colorectal cancer and gut microbiota studies in China
Wang, Z., Dan, W., Zhang, N., Fang, J., & Yang, Y. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2236364 · Cited by 173
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Microbiome and Breast Cancer: New Role for an Ancient Population
Eslami-S, Z., Majidzadeh-A, K., Halvaei, S., Babapirali, F., & Esmaeili, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00120 · Cited by 153
Microbiome dysbiosis in lung cancer: from composition to therapy
Liu, N., Ma, Q., Ge, Y., Yi, C., Wei, L., Tan, J.-C., Chu, Q., Li, J., Zhang, P., & Wang, H. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00138-z · Cited by 157
Self-citationExploring the Role of Gut Microbiome in Colon Cancer
Chattopadhyay, I., Dhar, R., Pethusamy, K., Seethy, A. A., Srivastava, T. P., Sah, R., Sharma, J. N., & Karmakar, S. (2021) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-021-03498-9 · Cited by 156
AIE-based theranostic systems for detection and killing of pathogens
He, X., Xiong, L.-H., Zhao, Z., Wang, Z., Luo, L., Lam, J. W. Y., Kwok, R. T. K., & Tang, B. Z. (2019) · Theranostics · doi:10.7150/thno.31844 · Cited by 151
The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.
Enright, E. F., Gahan, C. G. M., Joyce, S. A., & Griffin, B. T. (2016) · PubMed · Cited by 202
Intestinal bacteria and colorectal cancer: etiology and treatment
Dougherty, M. W., & Jobin, C. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185028 · Cited by 159
Self-citationMultiple NSAID-Induced Hits Injure the Small Intestine: Underlying Mechanisms and Novel Strategies
Boelsterli, U. A., Redinbo, M. R., & Saitta, K. S. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kfs310 · Cited by 142
Self-citationMicrobial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 158
Microbiota and cancer immunotherapy: in search of microbial signals
Gharaibeh, R. Z., & Jobin, C. (2019) · Gut · doi:10.1136/gutjnl-2018-317220 · Cited by 144
Self-citationCarcinogenesis and therapeutics: the microbiota perspective
Tsilimigras, M. C. B., Fodor, A., & Jobin, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.8 · Cited by 144
Self-citationExploring and Understanding the Biochemical Diversity of the Human Microbiota
Koppel, N., & Balskus, E. P. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.008 · Cited by 154
Immune Landscape of Breast Cancers
Nagarajan, D., & McArdle, S. (2018) · Biomedicines · doi:10.3390/biomedicines6010020 · Cited by 152
Metagenomics and novel gene discovery: Promise and potential for novel therapeutics
Culligan, E. P., Sleator, R. D., Marchesi, J. R., & Hill, C. (2013) · Virulence · doi:10.4161/viru.27208 · Cited by 163
Microbiota Effects on Carcinogenesis: Initiation, Promotion, and Progression
Lopez, L. R., Bleich, R. M., & Arthur, J. C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080719-091604 · Cited by 148
Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
Roberts, A. B., Wallace, B. D., Venkatesh, M. K., Mani, S., & Redinbo, M. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085852 · Cited by 140
“4A), whereas C2 crystallographic symmetry produced the physiologically relevant b-glucuronidase tetramer (Wallace et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationWang, H., Xie, H., Wang, J., Wu, J., Ma, X., Li, L., Wei, X., Ling, Q., Song, P., Zhou, L., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501953 · Cited by 138
Self-citationThe microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 144
Is It Time for a Metagenomic Basis of Therapeutics?
Haiser, H. J., & Turnbaugh, P. J. (2012) · Science · doi:10.1126/science.1224396 · Cited by 133
Nemet, I., Li, X. S., Haghikia, A., Li, L., Wilcox, J. D., Romano, K. A., Buffa, J. A., Witkowski, M., Demuth, I., König, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad333 · Cited by 143
Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Bagherian, M., Azami, N., Bejandi, A. K., Hushmandi, K., Ang, H. L., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111084 · Cited by 134
The mind-body-microbial continuum
Gonzalez, A., Stombaugh, J., Lozupone, C., Turnbaugh, P. J., Gordon, J. I., & Knight, R. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/agonzalez · Cited by 131
Models for drug absorption from the small intestine: where are we and where are we going?
Billat, P.-A., Roger, E., Faure, S., & Lagarce, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.007 · Cited by 125
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 143
Taylor, M. R., Flannigan, K. L., Rahim, H., Mohamud, A., Lewis, I. A., Hirota, S. A., & Greenway, S. C. (2019) · Science Advances · doi:10.1126/sciadv.aax2358 · Cited by 136
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Villéger, R., Lopès, A., Carrier, G., Veziant, J., Billard, E., Barnich, N., Gagnière, J., Vazeille, E., & Bonnet, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184584 · Cited by 119
Metagenomic Surveys of Gut Microbiota
Mandal, R. S., Saha, S., & Das, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.005 · Cited by 116
Mukherjee, S., Joardar, N., Sengupta, S., & Sinha Babu, S. P. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.010 · Cited by 124
Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism
Spanogiannopoulos, P., Kyaw, T. S., Guthrie, B. G. H., Bradley, P. H., Lee, J. V., Melamed, J., Malig, Y. N. A., Lam, K. N., Gempis, D., Sandy, M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01226-5 · Cited by 132
Armstrong, H., Bording-Jorgensen, M., Dijk, S., & Wine, E. (2018) · Cancers · doi:10.3390/cancers10030083 · Cited by 118
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 134
The effect of gut microbiota on drug metabolism
Kang, M. J., Kim, H. G., Kim, J. S., Oh, D. G., Um, Y. J., Seo, C. S., Han, J. W., Cho, H. J., Kim, G. H., Jeong, T. C., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.807798 · Cited by 120
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 121
Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway
Zhang, J., Dou, W., Zhang, E., Sun, A., Ding, L., Wei, X., Chou, G., Mani, S., & Wang, Z. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00465.2012 · Cited by 129
Self-citationMicrobiota in cancer development and treatment
Raza, M. H., Gul, K., Arshad, A., Riaz, N., Waheed, U., Rauf, A., Aldakheel, F. M., Alduraywish, S. A., Rehman, M. U., Abdullah, M., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2816-0 · Cited by 129
Wei, W., Liu, Y., Hou, Y., Cao, S., Chen, Z., Zhang, Y., Cai, X., Yan, Q., Li, Z., Yuan, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.026 · Cited by 126
Chamseddine, A. N., Ducreux, M. P., Armand, J., Paolettí, X., Satar, T., Paci, A., & Mir, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.002 · Cited by 126
Tsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D., & JOSEPH, D. R. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01032-y · Cited by 129
Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)
Chen, S., Yueh, M.-F., Bigo, C., Barbier, O., Wang, K., Karin, M., Nguyen, N., & Tukey, R. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319123110 · Cited by 121
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Scher, J. U., Nayak, R. R., Úbeda, C., Turnbaugh, P. J., & Abramson, S. B. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0395-3 · Cited by 121
Development of a covalent inhibitor of gut bacterial bile salt hydrolases
Adhikari, A. A., Seegar, T. C. M., Ficarro, S. B., McCurry, M. D., Ramachandran, D., Yao, L., Chaudhari, S. N., Ndousse-Fetter, S., Banks, A. S., Marto, J. A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0467-3 · Cited by 113
The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review
Liu, L., & Shah, K. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0494 · Cited by 111
Microbial enzymes induce colitis by reactivating triclosan in the mouse gastrointestinal tract
Zhang, J., Walker, M. E., Sanidad, K. Z., Zhang, H., Liang, Y., Zhao, E., Chacón-Vargas, K., Yeliseyev, V., Parsonnet, J., Haggerty, T. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27762-y · Cited by 117
Self-citationReynoso-García, J., Miranda-Santiago, A. E., Meléndez-Vázquez, N. M., Acosta-Pagán, K. T., Rosado, M. R. S., Díaz-Rivera, J., Rosado-Quiñones, A. M., Acevedo-Márquez, L., Cruz-Roldán, L., Tosado-Rodríguez, E. L., et al. (2022) · Frontiers in Systems Biology · doi:10.3389/fsysb.2022.951403 · Cited by 125
The gut microbiome and dietary fibres: implications in obesity, cardiometabolic diseases and cancer
Delzenne, N. M., Bindels, L. B., Neyrinck, A. M., & Walter, J. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01108-z · Cited by 126
The significance of microbiome in personalized medicine
Behrouzi, A., Nafari, A. H., & Siadat, S. D. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0232-y · Cited by 121
Roles of the gut microbiome in weight management
Carmody, R. N., & Bisanz, J. E. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00888-0 · Cited by 118
Yang, Y., Chen, G., Yang, Q., Ye, J., Cai, X., Tsering, P., Cheng, X., Hu, C., Zhang, S., & Cao, P. (2017) · Oncotarget · doi:10.18632/oncotarget.16458 · Cited by 118
Dou, W., Zhang, J., Zhang, E., Sun, A., Ding, L., Chou, G., Wang, Z., & Mani, S. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201863 · Cited by 111
Self-citationGut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment
Liu, Y., Lau, H. C.-H., Cheng, W. Y., & Yu, J. Q. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.07.002 · Cited by 119
Dashnyam, P., Mudududdla, R., Hsieh, T.-J., Lin, T.-C., Lin, H.-Y., Chen, P.-Y., Hsu, C.-Y., & Lin, C.-H. (2018) · Scientific Reports · doi:10.1038/s41598-018-34678-z · Cited by 108
The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke
Winek, K., Dirnagl, U., & Meisel, A. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0475-x · Cited by 108
Brown, J. M., & Hazen, S. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.765388 · Cited by 108
“The only other known example as of the writing of this review are the seminal studies by Redinbo and colleagues employing selective inhibition of microbial -glucuronidase to attenuate gastrointestinal toxicity of select cancer drugs and non-steroidal anti-inflammatory agents (77, 78).”
BackgroundPerspective and Guidelines for Metaproteomics in Microbiome Studies
Zhang, X., & Figeys, D. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00054 · Cited by 111
Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism
Dikeocha, I. J., Al‐Kabsi, A. M., Miftahussurur, M., & Alshawsh, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202101986r · Cited by 114
The colonic microbiota in health and disease
Shanahan, F. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a3493 · Cited by 102
Determining Microbial Products and Identifying Molecular Targets in the Human Microbiome
Joice, R., Yasuda, K., Shafquat, A., Morgan, X. C., & Huttenhower, C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.003 · Cited by 100
Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment
Pouncey, A. L., Scott, A. J., Alexander, J. L., Marchesi, J. R., & Kinross, J. K. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.868 · Cited by 114
Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases
Biernat, K. A., Pellock, S. J., Bhatt, A. P., Bivins, M. M., Walton, W. G., Trần, B. N., Wei, L., Snider, M. C., Cesmat, A. P., Tripathy, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36069-w · Cited by 108
Self-citationCommunity Health Care: Therapeutic Opportunities in the Human Microbiome
Sonnenburg, J. L., & Fischbach, M. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001626 · Cited by 102
Cheng, K.-W., Tseng, C.-H., Tzeng, C., Leu, Y.-L., Cheng, T.-C., Wang, J., Chang, J., Lu, Y., Cheng, C. C., Chen, I., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.029 · Cited by 107
The role of gut microbial β-glucuronidase in drug disposition and development
Gao, S., Sun, R., Singh, R., So, S. Y., Chan, C. T. Y., Savidge, T., & Hu, M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.001 · Cited by 107
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 109
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
The gut microbiota—a clinical perspective on lessons learned
Shanahan, F. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.145 · Cited by 105
Crosstalk between gut microbiota and host immune system and its response to traumatic injury
Ullah, H., Arbab, S., Tian, Y., Chen, Y., Liu, C., Li, Q., & Li, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413485 · Cited by 112
Unraveling the Role of the Human Gut Microbiome in Health and Diseases
Khalil, M., Ciaula, A. D., Mahdi, L., Jaber, N., Palo, D. M. D., Graziani, A., Baffy, G., & Portincasa, P. (2024) · Microorganisms · doi:10.3390/microorganisms12112333 · Cited by 114
Effects of microbiota on anticancer drugs: Current knowledge and potential applications
Huang, J., Liu, W., Kang, W., He, Y., Yang, R., Mou, X., & Zhao, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104197 · Cited by 103
Lin, X. B., Farhangfar, A., Valcheva, R., Sawyer, M. B., Dieleman, L., Schieber, A., Gänzle, M. G., & Baracos, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083644 · Cited by 96
TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine
Frank, M., Hennenberg, E. M., Eyking, A., Rünzi, M., Gerken, G., Scott, P., Parkhill, J., Walker, A. W., & Cario, E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402481 · Cited by 97
Evolving Concepts: How Diet and the Intestinal Microbiome Act as Modulators of Breast Malignancy
Shapira, I., Sultan, K., Lee, A., & Taioli, E. (2013) · ISRN Oncology · doi:10.1155/2013/693920 · Cited by 92
Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome
Yan, A., Culp, E., Perry, J., Lau, J. T., MacNeil, L. T., Surette, M. G., & Wright, G. D. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00166 · Cited by 97
Gut Microbiota and Breast Cancer: The Dual Role of Microbes
Álvarez‐Mercado, A. I., Cano, A. D. V., Fernández, M. F., & Fontana, L. (2023) · Cancers · doi:10.3390/cancers15020443 · Cited by 104
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98
Inamura, K., Hamada, T., Bullman, S., Ugai, T., Yachida, S., & Ogino, S. (2022) · Gut · doi:10.1136/gutjnl-2022-327209 · Cited by 100
Human β -Glucuronidase: Structure, Function, and Application in Enzyme Replacement Therapy
Naz, H. U., Islam, A., Waheed, A., Sly, W. S., Ahmad, F., & Hassan, M. I. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1407 · Cited by 97
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.